Results 321 to 330 of about 5,867,860 (378)

Paradigm Shift in Monoclonal Protein Detection: From Electrophoresis-based to Mass Spectrometry-based Methods. [PDF]

Ann Lab Med
Lee J, Yoo S, Yang S, Song SH.
europepmc   +1 more source

Beyond bacterial defences: the role of lysozyme in cancer

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
Lysozyme (LYZ) is a multi‐functional secreted factor that encompasses both antibacterial and immunomodulatory functions. Emerging evidence highlights its complex role in tumour progression by directly influencing tumour cells and modulating the immune microenvironment.
Lei Wang, Qian Dong, Fuchu He, Zhiwen Gu, Aihua Sun   +4 more
wiley   +1 more source

Novel proteomic characterization of multiple myeloma bone marrow interstitial fluid links prognosis to coagulation pathways. [PDF]

Clin Proteomics
Cutler S, Trottier AM, Liwski R, Quinn J, Gaston D, Veinotte R, Pierre JS, White D, Forward N, De La Torre A, Elnenaei M.   +10 more
europepmc   +1 more source

Tofacitinib‐Induced Weight Gain in Context: comment on the article by Wollenhaupt et al.

ACR Open Rheumatology, Volume 8, Issue 2, February 2026.
Andriko Palmowski, Frank Buttgereit, David Simon, Arnd Kleyer, Norman Michael Drzeniek   +4 more
wiley   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source

Immunodeficiency Diseases and Tumor Immunobiology [PDF]

, 1974
Abramoff, Peter A., Duquesnoy, Rene J.
core   +1 more source

Clinical applications of mass spectrometry in multiple myeloma. [PDF]

Blood Adv
Derman BA, Yee AJ.
europepmc   +1 more source

DNTTIP1 drives leukaemogenesis through MiDAC‐mediated epigenetic silencing of BMF

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
DNTTIP1 cooperates with SP1 to recruit HDAC1/2, leading to BMF silencing and reduced competitive binding of BMF to BCL2.This suppresses autophagy and apoptosis, promoting leukaemic cell survival. Targeting the DNTTIP1‐HDAC1/2‐BMF axis reactivates BMF and induces anti‐leukaemic effects.
Ruolin Xiu, Yuzhu Ma, Yueying Gao, Yao Chen, Xinyu Li, Yue Wu, Meiling Sun, Qizhao Li, Yanhong Zhao, Shuqian Xu, Shengjin Fan, Yongsheng Li, Huitao Fan   +12 more
wiley   +1 more source

Single-cell RNA sequencing reveals immune regulatory mechanisms and molecular therapeutic strategies in the microenvironment of multiple myeloma. [PDF]

Int J Surg
Su Q, Long K, Adu M, Jiang M, Li Q, Wan X, Cao J, Yue Y, Li S, Ying Z, Liu Q, You C, Zhang Z, Wang D.   +13 more
europepmc   +1 more source

Therapeutic Potential of Exportin 1 and Aurora Kinase A Inhibition in Multiple Myeloma Cells. [PDF]

Hematol Rep
Okabe S, Tanaka Y, Otsuki S, Moriyama M, Yoshizawa S, Gotoh A, Akahane D.   +6 more
europepmc   +1 more source